[Eosinophilia-myalgia syndrome].
The eosinophilia-myalgia syndrome was first reported from New Mexico, USA, in 1989. Since then, there have been further reports from the USA, Canada and Europe. Patients with the eosinophilia-myalgia syndrome present with myalgias, morbilliform and urticarial rash, oedema, sclerodermiform lesions, fever, pneumonia, fatigue and peripheral eosinophilia (greater than 1,000/mm3). The ultimate cause is postulated to be a contamination produced by Bacterium amyloliquefaciens during the production of L-tryptophan by genetic engineering techniques. HPLC analysis revealed that the causative agent was a condensation product of 1 mole acetaldehyde and 2 moles tryptophan. Clinical and laboratory findings of the eosinophilia-myalgia syndrome, Shulman syndrome and toxic-oil syndrome are discussed.
Reinauer
S
S
Hautklinik, Heinrich-Heine-Universität Düsseldorf.
Plewig
G
G
D000368:Aged; D001706:Biopsy; D004576:Electromyography / Q000187:drug effects; D004802:Eosinophilia / Q000139:chemically induced* / Q000175:diagnosis / Q000473:pathology; D005260:Female; D006801:Humans; D008875:Middle Aged; D009132:Muscles / Q000473:pathology; D009468:Neuromuscular Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000473:pathology; D010300:Parkinson Disease / Q000188:drug therapy*; D012595:Scleroderma, Systemic / Q000139:chemically induced* / Q000175:diagnosis / Q000473:pathology; D012867:Skin / Q000473:pathology; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy*; D013577:Syndrome; D014364:Tryptophan / Q000008:administration & dosage / Q000009:adverse effects*
D014364:Tryptophan
Das Eosinophilie-Myalgie-Syndrom.